Amarna Therapeutics, a privately held biotechnology company developing the next-generation SV40-based gene delivery vector platform, has entered into a collaboration with scientists from the Progreso y Salud Foundation (FPS) at Cabimer in Seville, to jointly examine the efficacy of Amarna’s SVec gene delivery vector to develop effective immunotherapies for diabetes mellitus type 1 (DM1) and multiple sclerosis (MS).   The collaboration is a joint effort between the research group of the FPS at re...